Glass House Brands Inc
Glass House Brands, Inc. operates as an integrated cannabis company in the United States with focus on the California market and building brands to serve consumers across various segments. The company is involved in greenhouse cultivation operations, manufacturing practices, brand-building, and retailing activities.…
1D
-14.3%
1W
-25.4%
1M
-60.4%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~38% weaker price swings than usual
PRICE TARGET LOW
US$15.00
CONSENSUS
US$16.00
MEDIAN
US$16.00
PRICE TARGET HIGH
US$17.00
No current analyst ratings available.
P/E
-4.93
P/B
3.49
EV/EBITDA
-17.16
RETURN ON EQUITY
-9.4%
NET MARGIN
-14.5%
DEBT/EQUITY
1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
–
FLOAT SHARES
69,602,837
AVG. DAILY VOLUME (30D)
1,567,971
Tu William
Tu William
Tu William
Tu William
Tu William
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -14.3%
Forums (Reddit)
Glass House Brands Inc is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in United States.
The CEO is Kyle Kazan, the company employs around 392 people.
The IPO was on 30/06/2026; the stock trades on NYSE under the ticker GLAS.
The average price target is US$16.00, ranging from US$15.00 to US$17.00, with a median of US$16.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -38% stronger than usual.
No, Glass House Brands currently does not pay a dividend.
Comparable stocks include Zoetis, Viatris, Lantheus Holdings, Amneal Pharmaceuticals, Indivior Pharmaceuticals, Eton Pharmaceuticals, Pacira BioSciences and Amphastar Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess Glass House Brands against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.